CYP450 Gene Variations and Their Implications for Drug Response: A Pharmacogenomic Review
The Human Genome Project (HGP) has significantly advanced our understanding of how human genetic variation affects drug response, particularly through metabolic enzymes such as Cytochrome P450 (CYP450). This study aimed to explore the impact of genetic variation on drug metabolism and its consequences for precision medicine therapies. This approach involved a literature review of various scientific articles discussing pharmacogenomics, CYP450 enzymes, and their clinical applications. The findings indicate that CYP450 enzymes are crucial in drug metabolism, especially during phase I reactions, such as oxidation, and their activity is heavily influenced by genetic polymorphisms, including those in CYP2C19. These genetic differences lead to variations in the ability of individuals to activate or eliminate drugs, thereby affecting the effectiveness of therapy and the likelihood of side effects. In addition to genetic factors, drug interactions, environmental influences, and the microbiome also play a role in drug response. For instance, genetic variation in the use of clopidogrel can result in therapeutic failure or a heightened risk of clinical events. Ultimately, integrating genomic data from the HGP with CYP450 enzyme profiles provides a vital basis for implementing precision medicine, allowing for more accurate drug and dosage selection, thereby enhancing therapeutic effectiveness and reducing the risk of side effects in patients.